By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monogram Orthopaedics Inc (MGRM – Research ...
GlobalData on MSN2d
Vivani Medical to spin-off neurostim business Cortigent as public companyVivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While Vivani ...
Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback